Crossmark Global Holdings Inc. Sells 85 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Crossmark Global Holdings Inc. trimmed its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 5.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,630 shares of the medical instruments supplier’s stock after selling 85 shares during the period. Crossmark Global Holdings Inc.’s holdings in ICU Medical were worth $253,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Hexagon Capital Partners LLC grew its holdings in shares of ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP increased its position in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 100 shares during the period. Venturi Wealth Management LLC raised its stake in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 302 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of ICU Medical in the third quarter valued at approximately $72,000. Finally, GAMMA Investing LLC increased its holdings in ICU Medical by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 571 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares during the period. Institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ICUI shares. KeyCorp raised their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Trading Down 0.0 %

NASDAQ ICUI opened at $172.28 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of -37.70 and a beta of 0.63. The firm has a 50 day simple moving average of $161.10 and a 200-day simple moving average of $161.42. ICU Medical, Inc. has a one year low of $86.80 and a one year high of $196.26.

Insider Activity

In related news, Director David C. Greenberg sold 972 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now directly owns 5,037 shares of the company’s stock, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,737 shares of company stock worth $4,941,832. 6.70% of the stock is currently owned by insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.